PHARMACYTE BIOTECH, INC. Payments for Repurchase of Redeemable Preferred Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PHARMACYTE BIOTECH, INC. payments for repurchase of redeemable preferred stock for the quarter ending 2024-01-31 was $2.25M.
- PHARMACYTE BIOTECH, INC. payments for repurchase of redeemable preferred stock for the quarter ending 2023-10-31 was $3.52M.
| Period end | Payments for Repurchase of Redeemable Preferred Stock 3 month | Payments for Repurchase of Redeemable Preferred Stock 12 month |
|---|---|---|
| 2024-01-31 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-18 | |
| 2023-10-31 | $3.52M 10-Q · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |